XML 74 R60.htm IDEA: XBRL DOCUMENT
v3.21.2

Collaboration, Licensing and Other Arrangements - Revenue Allocation (Detail) - Collaboration and License Agreement - United Therapeutics Corporation - USD ($) | 1 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Jun. 30, 2021 | Sep. 30, 2021 | May 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price |  | $ 50,900,000 |  | $ 50,200,000
R&D Services and License | Over Time |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price | [1] | $ 18,400,000 |  |
Progress Measure |  | Ratably |  |
Recognition Period |  | May 2021 - Oct 2021 |  |
Pre-Commercial Services | Over Time |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price | [1] | $ 4,600,000 |  |
Progress Measure |  | Input |  |
Recognition Period | [2] | % of completion of costs |  |
Next-Gen R&D Services | Over Time |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price | [1] | $ 7,200,000 |  |
Progress Measure |  | Input |  |
Recognition Period | [2] | % of completion of costs |  |
Facility Expansion Services | Point In Time |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price | [1],[3] | $ 20,700,000 |  |
Recognition Period | [3],[4] | Transfer of control |  |
Clinical Supplies |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price |  |  | $ 105,800,000 |
Clinical Supplies | R&D Services and License | Over Time |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Total transaction price |  |  | $ 105,800 |
Allocation of Price |  |  | 100.00% |
Progress Measure |  |  | Ratably |
Recognition Period | [5] |  | Sep 2018 - Dec 2021 |
[1] | Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.
[2] | Pre-Commercial Services and Next-Gen R&D Services performance obligations will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[3] | The Company will also be acting as agent for the procurement of equipment for the manufacturing expansion for the UT Equipment. The $5.3 million received from UT for the UT Equipment was recognized as deposits from customer on the condensed consolidated balance sheet and will be released as the title is transferred to UT
[4] | The Facility Expansion Services performance obligation would be recognized as control of manufactured products is transferred to the customer.
[5] | Recognition period represents the estimated period to satisfy the performance obligation.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045 + Details
Name: | us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of when remaining performance obligation is expected to be recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_ResearchAndDevelopmentServicesAndLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_PreCommercialServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_NextGenResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_FacilityExpansionServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerDurationAxis=mnkd_ClinicalSuppliesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |